Press releases
- UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
- Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
- Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
- Aurinia to Participate in Upcoming Investor Healthcare Conferences
- Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
- Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 16.87 |
Average volume | -- |
---|---|
Shares outstanding | 144.62m |
Free float | 133.85m |
P/E (TTM) | -- |
Market cap | 704.29m USD |
EPS (TTM) | -0.5454 USD |
Data delayed at least 20 minutes, as of Nov 09 2021.
More ▼